tumor antigens

tu·mor an·ti·gens

1. antigens that may be frequently associated with tumors or may be specifically found on tumor cells of the same origin (tumor specific);
2. tumor antigens may also be associated with replication and transformation by certain DNA tumor viruses, including adenoviruses and papovaviruses.
Synonym(s): neoantigens (2)

See also: T antigens.

tu·mor an·ti·gens

(tū'mŏr an'ti-jenz)
1. Those antigens that may be frequently associated with tumors or may be specifically found on tumor cells of the same origin (tumor specific).
2. Tumor antigens may also be associated with replication and transformation by certain DNA tumor viruses, including adenoviruses and papovaviruses.
See also: T antigens
Synonym(s): neoantigens, tumour antigens.
References in periodicals archive ?
Thus, Advaxis believes ADXS-NEO may be able to induce a specific immune response against neoantigen-bearing tumor cells with the resultant cell death releasing secondary (nontargeted) tumor antigens. These secondary antigens can then prime subsequent immune responses (antigen spread) that are thought to be responsible for the improved clinical outcomes documented with other immunotherapies.
ADXS-NEO is a personalised immunotherapy that is designed to help a patient's immune system recognize and respond to mutation-derived tumor antigens, or neoantigens, that are unique to his or her tumor.
ADXS-NEO is a personalized immunotherapy that is designed to help a patient's immune system recognize and respond to mutation-derived tumor antigens, or neoantigens, that are unique to his or her tumor.
Jude will explore a new approach to cellular immunotherapy by targeting multiple tumor antigens with CARs using Tessa's VST platform.
The company said the ROOT OF CANCER treatment consists of the patient's own dendritic cells loaded with tumor antigens from the patient's own tumor-initiating cells.
MONDAY, June 4, 2018 (HealthDay News) -- A highly personalized therapy targeting multiple tumor antigens shows promise for metastatic breast cancer, according to a research letter published online June 4 in Nature Medicine.
mAbs were later found to be able to bind biological targets like tumor antigens, molecules involved in autoimmune and infectious disease-related molecules, etc This led to emergence of therapeutic monoclonal antibodies.
The tumor antigens must be presented to the body in a different form, or in a different way, to enlist the patient's own immune system in fighting the cancer.
Firstly, and most importantly, there is a robust ability for TCR-transduced T cells to be generated against a plethora of tumor antigens [78].
Tumor antigens that are normally hidden from the immune system inside the cells are released, triggering an immune response to fight the tumor.
CytomX has generated preclinical data that demonstrates that Probody drug conjugates can safely and effectively target tumor antigens, such as CD71, that are not addressable by conventional antibody-drug conjugates.
Creation of a pure population of T cells, based on targeted screening for specific features, such as affinity to tumor antigens and anti-tumor activity, enables isolation of a single population of TCRs, which can then be sequenced.